A Bivalent Supramolecular GCP Ligand Enables Blocking of the Taspase1/Importin α Interaction

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Taspase1 is a crucial protease in development and implicated in various cancers.
• Existing Taspase1 inhibitors have limited applicability.
• Targeting the Taspase1-Importin α interaction presents a novel therapeutic strategy.

Purpose of the Study:

• To develop a novel supramolecular ligand targeting the Taspase1-Importin α interaction.
• To evaluate the efficacy of this ligand in vitro and in cancer cell lines.
• To explore a new class of Taspase1 inhibitors for cancer therapy.

Main Methods:

• Design and synthesis of a bivalent guanidiniocarbonyl-pyrrole (GCP) supramolecular ligand.
• In vitro assays to assess the disruption of Taspase1-Importin α interaction (IC50 determination).
• Evaluation of the ligand's effects in various tumor cell lines (EC50 determination).

Main Results:

• The bivalent GCP ligand effectively disrupted the Taspase1-Importin α interaction in vitro (IC50 = 35 μM).
• Ligand size and cbz-group derivation were critical for efficient inhibition.
• Comparable efficacy was observed in tumor cell lines (EC50 ≈ 40-70 μM).
• Higher concentrations also inhibited Taspase1's proteolytic activity.

Conclusions:

• A novel bivalent supramolecular ligand effectively targets the Taspase1-Importin α interaction.
• This approach offers a promising strategy for developing Taspase1 inhibitors.
• The study lays the groundwork for a new class of cancer therapeutics targeting protein-protein interactions crucial for cancer progression.